Spyre Therapeutics, Inc. (SYRE)
SYRE moved a median of +0.36% 30 minutes after news, and +0.35% by the close. How SYRE actually reacts to news — the realized, point-in-time move the market made, measured across 382 labeled events over the last three years with zero look-ahead.
SYRE’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.29% | 60% | 378 |
| 30-min | +0.36% | 57% | 381 |
| 60-min | +0.29% | 54% | 381 |
| to close | +0.35% | 52% | 377 |
| Middle 50% of SYRE reactions | -1.09% to +1.99% |
|---|---|
| Median reaction (30-min) | +0.36% |
| Measured reactions | 382 |
Half of all Spyre Therapeutics, Inc. news events land between -1.09% and +1.99% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How SYRE reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 15 | -0.26% | 40% | -1.24% |
| Coverage initiations | 40 | -1.33% | 40% | -1.21% |
| Rating reiterations | 56 | +0.15% | 57% | +0.34% |
| Price-target raises | 18 | -0.48% | 44% | -1.23% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how SYRE ranks against every other measured name →
That’s how SYRE usually reacts — get an email when it moves on news →Email me when SYRE moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to SYRE's baseline. Nothing else.
Recent SYRE events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K Spyre Therapeutics, Inc. For: Oct 05 | SEC filing · Form 8-K | SEC EDGAR | +2.69% | +2.46% | |
| Spyre Therapeutics Announces Pricing of $350.0 Million Public Offering of Common Stock | Press release | GlobeNewswire | -2.66% | -13.00% | |
| Spyre Therapeutics Announces Proposed Public Offering of its Common Stock | Press release | GlobeNewswire | -2.66% | -13.00% | |
| Spyre Therapeutics Announces Grants of Inducement Awards | Press release | GlobeNewswire | +0.88% | -0.32% | |
| Form 8-K Spyre Therapeutics, Inc. For: Sep 08 | SEC filing · Form 8-K | SEC EDGAR | +1.63% | +6.71% | |
| Spyre Announces Potential Best-in-Class SPY003 (anti-IL-23) Part A Induction Results from SKYLINE Trial, Completing Proof-of-Concept for All Three Components of its IBD Combinations | Press release | GlobeNewswire | +1.63% | +6.71% | |
| Spyre Therapeutics Announces Grants of Inducement Awards | Press release | GlobeNewswire | +1.63% | +6.71% | |
| Spyre Therapeutics to Participate in Upcoming September Investor Conferences | Press release | GlobeNewswire | +0.89% | +2.93% | |
| Form 8-K Spyre Therapeutics, Inc. For: Aug 25 | SEC filing · Form 8-K | SEC EDGAR | +0.51% | +1.75% | |
| Spyre Therapeutics Announces Topline Results from the Rheumatoid Arthritis Sub-study of the SKYWAY Phase 2 Trial of SPY072 | Press release | GlobeNewswire | +0.51% | +1.75% | |
| Spyre Therapeutics Announces Launch of SPY772 Program and Initiation of Phase 2 SKYLIGHT Trial in Hidradenitis Suppurativa | Press release | GlobeNewswire | +0.74% | — | |
| Spyre Therapeutics Announces Grants of Inducement Awards | Press release | GlobeNewswire | +0.74% | — | |
| Form 10-Q Spyre Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +2.05% | -0.56% | |
| Form 8-K Spyre Therapeutics, Inc. For: Aug 04 | SEC filing · Form 8-K | SEC EDGAR | +2.05% | -0.56% | |
| Spyre Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | +2.05% | -0.56% | |
| Spyre Therapeutics Announces Grants of Inducement Awards | Press release | GlobeNewswire | +1.08% | +1.68% | |
| Form S-3ASR Spyre Therapeutics, Inc. | SEC filing · Form S-3ASR | SEC EDGAR | +0.24% | +3.63% | |
| Form 8-K Spyre Therapeutics, Inc. For: Jun 15 | SEC filing · Form 8-K | SEC EDGAR | +2.39% | +2.46% | |
| Spyre Announces Potential Best-in-Class SPY002 (anti-TL1A) Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients | Press release | GlobeNewswire | +2.39% | +2.46% | |
| Spyre Therapeutics Announces Grants of Inducement Awards | Press release | GlobeNewswire | +0.23% | -4.67% | |
| Spyre Therapeutics Announces Completion of Enrollment in SKYWAY Basket Trial Evaluating SPY072 (anti-TL1A) in RA, PsA, and axSpA | Press release | GlobeNewswire | +5.58% | +5.03% | |
| Form 8-K Spyre Therapeutics, Inc. For: May 29 | SEC filing · Form 8-K | SEC EDGAR | -1.29% | -1.19% | |
| Form 8-K Spyre Therapeutics, Inc. For: May 27 | SEC filing · Form 8-K | SEC EDGAR | -1.77% | -2.22% | |
| Spyre Therapeutics to Participate in Upcoming June Investor Conferences | Press release | GlobeNewswire | -1.28% | -2.00% | |
| Form 10-Q Spyre Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +1.60% | +1.07% | |
| Form 8-K Spyre Therapeutics, Inc. For: May 05 | SEC filing · Form 8-K | SEC EDGAR | +1.60% | +1.07% | |
| Spyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | +1.60% | +1.07% | |
| Spyre Therapeutics Announces Grants of Inducement Awards | Press release | GlobeNewswire | +3.17% | +1.56% | |
| Form 8-K Spyre Therapeutics, Inc. For: Apr 14 | SEC filing · Form 8-K | SEC EDGAR | +0.87% | +3.83% | |
| Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $463.5 Million | Press release | GlobeNewswire | +0.87% | +3.83% | |
| Spyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common Stock | Press release | GlobeNewswire | -1.96% | +1.83% | |
| Form 8-K Spyre Therapeutics, Inc. For: Apr 13 | SEC filing · Form 8-K | SEC EDGAR | +0.16% | -5.57% | |
| Spyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients | Press release | GlobeNewswire | +0.16% | -5.57% | |
| Spyre Therapeutics Announces Proposed Public Offering of its Common Stock | Press release | GlobeNewswire | -3.74% | -3.69% | |
| Form ARS Spyre Therapeutics, Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.16% | -5.57% | |
| Form DEF 14A Spyre Therapeutics, Inc. For: May 27 | SEC filing · Form DEF | SEC EDGAR | +0.16% | -5.57% | |
| Form DEFA14A Spyre Therapeutics, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +0.16% | -5.57% | |
| Spyre Therapeutics to Host Conference Call to Report SPY001 Part A Induction Topline Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients on April 13, 2026 | Press release | GlobeNewswire | +0.16% | -5.57% | |
| Spyre Therapeutics Announces Grants of Inducement Awards | Press release | GlobeNewswire | +3.27% | +4.68% | |
| Spyre Announces Acceleration of Expected Topline Readout of SKYWAY Rheumatoid Arthritis Sub-study to Q3 2026 | Press release | GlobeNewswire | +3.18% | +8.20% | |
| Spyre Therapeutics Announces Grants of Inducement Awards | Press release | GlobeNewswire | +2.83% | +3.32% | |
| Form EFFECT Spyre Therapeutics, Inc. | SEC filing · Form EFFECT | SEC EDGAR | +0.15% | +0.35% | |
| Form EFFECT Spyre Therapeutics, Inc. | SEC filing · Form EFFECT | SEC EDGAR | +2.69% | +2.96% | |
| Form POS AM Spyre Therapeutics, Inc. | SEC filing · Form POS | SEC EDGAR | +2.69% | +2.96% | |
| Spyre Therapeutics to Participate in Upcoming March Investor Conferences | Press release | GlobeNewswire | -0.09% | -0.68% | |
| Form 10-K Spyre Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +2.25% | +14.25% | |
| Form 8-K Spyre Therapeutics, Inc. For: Feb 19 | SEC filing · Form 8-K | SEC EDGAR | +2.25% | +14.25% | |
| Form S-3 Spyre Therapeutics, Inc. | SEC filing · Form S-3 | SEC EDGAR | +2.25% | +14.25% | |
| Form S-8 Spyre Therapeutics, Inc. | SEC filing · Form S-8 | SEC EDGAR | +2.25% | +14.25% | |
| Spyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | +2.25% | +14.25% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the SYRE section they belong to.
Where else SYRE is measured.
SYRE earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Spyre Therapeutics, Inc.'s median reaction calculated?
Every labeled SYRE news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 382 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 57% of SYRE's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does SYRE's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.